Upstream Bio, Inc. (NASDAQ:UPB) Receives $29.67 Average Price Target from Analysts

Upstream Bio, Inc. (NASDAQ:UPB) has earned an average rating of “Hold” from the seven brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $29.6667.

A number of analysts recently weighed in on UPB shares. HC Wainwright began coverage on Upstream Bio in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 price target on the stock. Weiss Ratings upgraded Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 17th. Mizuho decreased their target price on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th. Wall Street Zen cut shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, JPMorgan Chase & Co. increased their price target on shares of Upstream Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Friday, August 14th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in Upstream Bio in the second quarter valued at $25,973,000. Norges Bank purchased a new position in shares of Upstream Bio during the fourth quarter valued at approximately $78,264,000. Vanguard Group Inc. grew its position in shares of Upstream Bio by 12.5% in the third quarter. Vanguard Group Inc. now owns 2,442,551 shares of the company’s stock valued at $45,944,000 after purchasing an additional 271,718 shares during the period. UBS Group AG lifted its holdings in shares of Upstream Bio by 563.4% during the 4th quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock worth $49,039,000 after acquiring an additional 1,533,972 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in Upstream Bio during the fourth quarter worth approximately $41,423,000.

Upstream Bio Stock Down 1.0%

NASDAQ UPB opened at $6.62 on Tuesday. The stock has a market capitalization of $362.58 million, a P/E ratio of -2.28 and a beta of 1.26. Upstream Bio has a 52-week low of $5.85 and a 52-week high of $33.68. The firm has a 50-day moving average price of $6.95 and a 200 day moving average price of $8.03.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.01. The company had revenue of $0.77 million for the quarter, compared to analyst estimates of $0.56 million. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%. On average, equities research analysts expect that Upstream Bio will post -2.86 earnings per share for the current fiscal year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.